ID

38074

Descrizione

Two-Part Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Oral Dosesof the Enteric-Coated Free Base Formulation of Darapladib (SB-480848) ina Dose Rising Fashion and to Evaluate the Safety, Tolerability and Pharmacokinetics of Darapladib when Co-administered with Ketoconazole in Healthy Adult Subjects. There are 4 parts to this study: Screening, Part A, Part B, and Follow-Up. Part A contains 2 Sessions per day for day 1-10, Part B contains 1 Session per day for day 1-14. Each itemgroup contains information when it should be filled out. The itemgroups of the non-serious and serious adverse event forms contain additional information on the definition of a serious/non-serious adverse event.

Keywords

versioni (1)
  1. 15/09/19 15/09/19 -
Titolare del copyright

GlaxoSmithKline

Caricato su

15 settembre 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Darapladib Evaluation Case Report Form GSK LPL107988

Inglese

Eligibility Criteria

12 moduli  
Administrative documentation
Descrizione

Administrative documentation

Alias
UMLS CUI-1
C1320722
Subject Identifier
Descrizione

Subject Identifier

Tipo di dati

text

Alias
UMLS CUI [1]
C2348585
Visit Date
Descrizione

Visit Date

Tipo di dati

date

Alias
UMLS CUI [1]
C1320303
Eligibility Criteria General
Descrizione

Eligibility Criteria General

Alias
UMLS CUI-1
C1516637
Did the subject meet all the entry criteria?
Descrizione

Entry criteria fulfilled

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1550543
UMLS CUI [1,2]
C1516637
Eligibility Criteria - Inclusion Criteria
Descrizione

Eligibility Criteria - Inclusion Criteria

Alias
UMLS CUI-1
C1516637
UMLS CUI-2
C1512693
Is the participant healthy as determined by a responsible physician, based on a medical evaluation including history, physical examination, laboratory tests and cardiac monitoring?
Descrizione

A subject with a clinical abnormality or laboratory parameters outside the reference range may be included only if the Investigator considers that the finding will not introduce additional risk factors and will not interfere with the study procedures.

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C3898900
UMLS CUI [1,3]
C0521095
UMLS CUI [1,4]
C0031831
UMLS CUI [1,5]
C3826004
UMLS CUI [2]
C0262926
UMLS CUI [3]
C0031809
UMLS CUI [4]
C0022885
UMLS CUI [5]
C0150496
Is the participant between 18 and 65 years of age, inclusive?
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
Is the body weight > 50 kg (110 pounds) and body mass index (BMI) between 19 and 30?
Descrizione

BMI = Weight in kg/(height in meters)^2

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0005910
UMLS CUI [2]
C1305855
Is the participant capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form?
Descrizione

Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2698977
UMLS CUI [1,2]
C0021430
UMLS CUI [2,1]
C1321605
UMLS CUI [2,2]
C0009797
Eligibility Criteria - Exclusion Criteria
Descrizione

Eligibility Criteria - Exclusion Criteria

Alias
UMLS CUI-1
C1516637
UMLS CUI-2
C0680251
Does the participant have any clinically relevant abnormality identified on the screening medical assessment, laboratory examination or ECG?
Descrizione

Clinically relevant abnormality

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0205210
UMLS CUI [1,2]
C2347946
UMLS CUI [1,3]
C1704258
UMLS CUI [1,4]
C0582103
UMLS CUI [2,1]
C0205210
UMLS CUI [2,2]
C2347946
UMLS CUI [2,3]
C1704258
UMLS CUI [2,4]
C0260877
UMLS CUI [3,1]
C0205210
UMLS CUI [3,2]
C2347946
UMLS CUI [3,3]
C1704258
UMLS CUI [3,4]
C0013798
Does the participant have a history of asthma, anaphylaxis or anaphalactoid reactions, severe allergic responses?
Descrizione

Asthma, Anaphylaxis, anaphylactoid reactions or severe allergic responses

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0004096
UMLS CUI [2,1]
C0262926
UMLS CUI [2,2]
C0002792
UMLS CUI [3,1]
C0262926
UMLS CUI [3,2]
C0340865
UMLS CUI [4,1]
C0262926
UMLS CUI [4,2]
C1527304
UMLS CUI [4,3]
C0205082
Does the participant have a history of regular alcohol consumption averaging >7 drinks/week for women or >14 drinks/week for men within 6 months of screening?
Descrizione

one drink is equivalent to 12 g alcohol = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of 80 proof distilled spirits

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001948
Does the subject have a positive pre-study urine drug/ urine alcohol screen?
Descrizione

A minimum list of drugs that will be screened for include Amphetamines, Barbiturates, Cocaine, Opiates, Cannabinoids and Benzodiazepines

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1527048
UMLS CUI [1,2]
C0202274
UMLS CUI [1,3]
C1446409
UMLS CUI [2,1]
C1527048
UMLS CUI [2,2]
C0420032
UMLS CUI [2,3]
C1446409
Is the subject positive for HIV, Hepatitis B or Hepatitis C at screening?
Descrizione

HIV, Hepatitis B or Hepatitis C positive

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019699
UMLS CUI [2]
C0856706
UMLS CUI [3]
C1112419
Does the subject use prescription (including hormone replacement) or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort)?
Descrizione

This refers to within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and sponsor the medication will not interfere with the study procedures or compromise subject safety. An exception is acetaminophen which is allowed at doses of < 2g/day.

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0457083
UMLS CUI [1,2]
C0304227
UMLS CUI [2,1]
C0457083
UMLS CUI [2,2]
C0013231
UMLS CUI [3]
C0042890
UMLS CUI [4]
C1504473
UMLS CUI [5]
C0242295
Does the subject have exposure to more than four new chemical entities within 12 months prior to the first dosing day?
Descrizione

Exposure to new chemical entities

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C0205314
UMLS CUI [1,3]
C0220806
UMLS CUI [1,4]
C0332152
UMLS CUI [1,5]
C0205435
UMLS CUI [1,6]
C0439228
Has the subject participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication?
Descrizione

Received clinical trial medication recently

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C0008976
UMLS CUI [1,3]
C0205394
UMLS CUI [2,1]
C0332185
UMLS CUI [2,2]
C0332157
UMLS CUI [2,3]
C0205314
UMLS CUI [2,4]
C0220806
UMLS CUI [2,5]
C0332152
UMLS CUI [2,6]
C0332185
Did the subject consume grapefruit or grapefruit juice within 7 days prior to the first dose of study medication?
Descrizione

Grapefruit juice consumption

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0995150
UMLS CUI [1,2]
C0009830
UMLS CUI [1,3]
C0332185
UMLS CUI [2,1]
C0452456
UMLS CUI [2,2]
C0009830
UMLS CUI [2,3]
C0332185
Does the participant have a history of cholecystectomy or biliary tract disease including a history of liver disease with elevated liver function tests of known or unknown etiology?
Descrizione

Cholecystectomy or biliary tract disease

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0008320
UMLS CUI [2,1]
C0262926
UMLS CUI [2,2]
C0005424
UMLS CUI [3,1]
C0262926
UMLS CUI [3,2]
C0023895
UMLS CUI [3,3]
C3163633
UMLS CUI [3,4]
C0023901
Is the subject pregnant or nursing?
Descrizione

For female subjects, a positive serum β-hCG at screening or pre-dose of any session; or for female subjects of childbearing potential an unwillingness to agree to one of the methods of contraception listed in Protocol Section 7.3 from screening until the completion of follow-up procedures.

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Does the subject have a use of oral, injected and implanted hormonal methods of contraception (for female subjects)?
Descrizione

Contraceptive method

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0442027
UMLS CUI [1,2]
C0458083
UMLS CUI [1,3]
C0700589
UMLS CUI [2,1]
C2986768
UMLS CUI [2,2]
C0458083
UMLS CUI [2,3]
C0700589
UMLS CUI [3,1]
C0021102
UMLS CUI [3,2]
C0458083
UMLS CUI [3,3]
C0700589
Would participation in the study result in donation of blood in excess of 500 mL within a 56 day period?
Descrizione

Excess blood donation

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C0553700
UMLS CUI [1,3]
C0442802
Does the participant have a history of sensitivity to any of the study medications (including ketoconazole for Part B only), or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation?
Descrizione

Sensitivity to study medication

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C4284232
UMLS CUI [1,3]
C0008976
UMLS CUI [1,4]
C0522473
UMLS CUI [1,5]
C2348568
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0184498
UMLS CUI [2,3]
C0008976
UMLS CUI [2,4]
C0522473
UMLS CUI [2,5]
C2348568
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0205394
UMLS CUI [3,3]
C0522473
UMLS CUI [3,4]
C2348568
Does the participant have a history of sensitivity to heparin or heparin-induced thrombocytopenia (if heparin is to be used for flushing a cannula)?
Descrizione

Heparin sensitivity or HIT

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0272285
UMLS CUI [2,1]
C0262926
UMLS CUI [2,2]
C0019134
UMLS CUI [2,3]
C0020517
Does the subject have a use of other CYP 3A4 inhibitors or inducers within 14 days prior to dosing of study medication (Part B only)?
Descrizione

CYP3A4 inducers

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0457083
UMLS CUI [1,2]
C3830625
UMLS CUI [1,3]
C0332185
UMLS CUI [2,1]
C0457083
UMLS CUI [2,2]
C3830624
UMLS CUI [2,3]
C0332185
Ritorna all'inizio della pagina

Similar models

Eligibility Criteria

12 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Administrative documentation
C1320722 (UMLS CUI-1)
Subject Identifier
Item
Subject Identifier
text
C2348585 (UMLS CUI [1])
Visit Date
Item
Visit Date
date
C1320303 (UMLS CUI [1])
Item Group
Eligibility Criteria General
C1516637 (UMLS CUI-1)
Entry criteria fulfilled
Item
Did the subject meet all the entry criteria?
boolean
C1550543 (UMLS CUI [1,1])
C1516637 (UMLS CUI [1,2])
Item Group
Eligibility Criteria - Inclusion Criteria
C1516637 (UMLS CUI-1)
C1512693 (UMLS CUI-2)
Participant Healthy
Item
Is the participant healthy as determined by a responsible physician, based on a medical evaluation including history, physical examination, laboratory tests and cardiac monitoring?
boolean
C0681850 (UMLS CUI [1,1])
C3898900 (UMLS CUI [1,2])
C0521095 (UMLS CUI [1,3])
C0031831 (UMLS CUI [1,4])
C3826004 (UMLS CUI [1,5])
C0262926 (UMLS CUI [2])
C0031809 (UMLS CUI [3])
C0022885 (UMLS CUI [4])
C0150496 (UMLS CUI [5])
Age
Item
Is the participant between 18 and 65 years of age, inclusive?
boolean
C0001779 (UMLS CUI [1])
Weight and BMI
Item
Is the body weight > 50 kg (110 pounds) and body mass index (BMI) between 19 and 30?
boolean
C0005910 (UMLS CUI [1])
C1305855 (UMLS CUI [2])
Informed Consent
Item
Is the participant capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form?
boolean
C2698977 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
C1321605 (UMLS CUI [2,1])
C0009797 (UMLS CUI [2,2])
Item Group
Eligibility Criteria - Exclusion Criteria
C1516637 (UMLS CUI-1)
C0680251 (UMLS CUI-2)
Clinically relevant abnormality
Item
Does the participant have any clinically relevant abnormality identified on the screening medical assessment, laboratory examination or ECG?
boolean
C0205210 (UMLS CUI [1,1])
C2347946 (UMLS CUI [1,2])
C1704258 (UMLS CUI [1,3])
C0582103 (UMLS CUI [1,4])
C0205210 (UMLS CUI [2,1])
C2347946 (UMLS CUI [2,2])
C1704258 (UMLS CUI [2,3])
C0260877 (UMLS CUI [2,4])
C0205210 (UMLS CUI [3,1])
C2347946 (UMLS CUI [3,2])
C1704258 (UMLS CUI [3,3])
C0013798 (UMLS CUI [3,4])
Asthma, Anaphylaxis, anaphylactoid reactions or severe allergic responses
Item
Does the participant have a history of asthma, anaphylaxis or anaphalactoid reactions, severe allergic responses?
boolean
C0262926 (UMLS CUI [1,1])
C0004096 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0002792 (UMLS CUI [2,2])
C0262926 (UMLS CUI [3,1])
C0340865 (UMLS CUI [3,2])
C0262926 (UMLS CUI [4,1])
C1527304 (UMLS CUI [4,2])
C0205082 (UMLS CUI [4,3])
Alcohol consumption
Item
Does the participant have a history of regular alcohol consumption averaging >7 drinks/week for women or >14 drinks/week for men within 6 months of screening?
boolean
C0001948 (UMLS CUI [1])
Positive Drug or alcohol screen
Item
Does the subject have a positive pre-study urine drug/ urine alcohol screen?
boolean
C1527048 (UMLS CUI [1,1])
C0202274 (UMLS CUI [1,2])
C1446409 (UMLS CUI [1,3])
C1527048 (UMLS CUI [2,1])
C0420032 (UMLS CUI [2,2])
C1446409 (UMLS CUI [2,3])
HIV, Hepatitis B or Hepatitis C positive
Item
Is the subject positive for HIV, Hepatitis B or Hepatitis C at screening?
boolean
C0019699 (UMLS CUI [1])
C0856706 (UMLS CUI [2])
C1112419 (UMLS CUI [3])
Medication or supplement use
Item
Does the subject use prescription (including hormone replacement) or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort)?
boolean
C0457083 (UMLS CUI [1,1])
C0304227 (UMLS CUI [1,2])
C0457083 (UMLS CUI [2,1])
C0013231 (UMLS CUI [2,2])
C0042890 (UMLS CUI [3])
C1504473 (UMLS CUI [4])
C0242295 (UMLS CUI [5])
Exposure to new chemical entities
Item
Does the subject have exposure to more than four new chemical entities within 12 months prior to the first dosing day?
boolean
C0332157 (UMLS CUI [1,1])
C0205314 (UMLS CUI [1,2])
C0220806 (UMLS CUI [1,3])
C0332152 (UMLS CUI [1,4])
C0205435 (UMLS CUI [1,5])
C0439228 (UMLS CUI [1,6])
Received clinical trial medication recently
Item
Has the subject participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication?
boolean
C2348568 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C0332185 (UMLS CUI [2,1])
C0332157 (UMLS CUI [2,2])
C0205314 (UMLS CUI [2,3])
C0220806 (UMLS CUI [2,4])
C0332152 (UMLS CUI [2,5])
C0332185 (UMLS CUI [2,6])
Grapefruit juice consumption
Item
Did the subject consume grapefruit or grapefruit juice within 7 days prior to the first dose of study medication?
boolean
C0995150 (UMLS CUI [1,1])
C0009830 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0452456 (UMLS CUI [2,1])
C0009830 (UMLS CUI [2,2])
C0332185 (UMLS CUI [2,3])
Cholecystectomy or biliary tract disease
Item
Does the participant have a history of cholecystectomy or biliary tract disease including a history of liver disease with elevated liver function tests of known or unknown etiology?
boolean
C0262926 (UMLS CUI [1,1])
C0008320 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0005424 (UMLS CUI [2,2])
C0262926 (UMLS CUI [3,1])
C0023895 (UMLS CUI [3,2])
C3163633 (UMLS CUI [3,3])
C0023901 (UMLS CUI [3,4])
Pregnant or nursing
Item
Is the subject pregnant or nursing?
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Contraceptive method
Item
Does the subject have a use of oral, injected and implanted hormonal methods of contraception (for female subjects)?
boolean
C0442027 (UMLS CUI [1,1])
C0458083 (UMLS CUI [1,2])
C0700589 (UMLS CUI [1,3])
C2986768 (UMLS CUI [2,1])
C0458083 (UMLS CUI [2,2])
C0700589 (UMLS CUI [2,3])
C0021102 (UMLS CUI [3,1])
C0458083 (UMLS CUI [3,2])
C0700589 (UMLS CUI [3,3])
Excess blood donation
Item
Would participation in the study result in donation of blood in excess of 500 mL within a 56 day period?
boolean
C2348568 (UMLS CUI [1,1])
C0553700 (UMLS CUI [1,2])
C0442802 (UMLS CUI [1,3])
Sensitivity to study medication
Item
Does the participant have a history of sensitivity to any of the study medications (including ketoconazole for Part B only), or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation?
boolean
C0020517 (UMLS CUI [1,1])
C4284232 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C0522473 (UMLS CUI [1,4])
C2348568 (UMLS CUI [1,5])
C0020517 (UMLS CUI [2,1])
C0184498 (UMLS CUI [2,2])
C0008976 (UMLS CUI [2,3])
C0522473 (UMLS CUI [2,4])
C2348568 (UMLS CUI [2,5])
C0020517 (UMLS CUI [3,1])
C0205394 (UMLS CUI [3,2])
C0522473 (UMLS CUI [3,3])
C2348568 (UMLS CUI [3,4])
Heparin sensitivity or HIT
Item
Does the participant have a history of sensitivity to heparin or heparin-induced thrombocytopenia (if heparin is to be used for flushing a cannula)?
boolean
C0262926 (UMLS CUI [1,1])
C0272285 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0019134 (UMLS CUI [2,2])
C0020517 (UMLS CUI [2,3])
CYP3A4 inducers
Item
Does the subject have a use of other CYP 3A4 inhibitors or inducers within 14 days prior to dosing of study medication (Part B only)?
boolean
C0457083 (UMLS CUI [1,1])
C3830625 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0457083 (UMLS CUI [2,1])
C3830624 (UMLS CUI [2,2])
C0332185 (UMLS CUI [2,3])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial